// App-Quantinova.ai

5035 : Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).

Researchers

Presenter

  • Martin Fleisher

Principal Investigators

  • Daniel Costin Danila

  • De Phung

  • Johann Sebastian De Bono

  • Howard I. Scher

  • Karim Fizazi

  • Mohammad Hirmand

  • Brian Selby

Medical Centers

  • Medication, Inc., San Francisco, CA

  • Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, FranceAstellas Pharma Global Development, Inc., Leiderdorp, Netherlands

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Medication, Inc., San Francisco, CA

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Locations

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Lactate dehydrogenase

Drug/Treatment

  • Enzalutamide

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved